GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RegeneRx Biopharmaceuticals RGRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

RegeneRx Biopharmaceuticals — daily RGRX Delayed
Market value
$1,579
Last close × shares
Volume
252
Shares, 30 Oct 2026

About RegeneRx Biopharmaceuticals

Its shares trade under the ticker RGRX. It has been listed since 23 December 1986. In the fiscal year to 31 December 2022, it reported revenue of $76,761 and a net loss of $1.7m. At that date it held total assets of $382,177 and shareholders' equity of −$3.4m.

RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. The company is headquartered in Rockville, Maryland. The firm is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The firm's segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The firm has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Figures and description from our data supplier, not checked against the company's own report.

More about RegeneRx Biopharmaceuticals →

Latest on RegeneRx Biopharmaceuticals

Our reporting

We have not reported on RegeneRx Biopharmaceuticals yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is RegeneRx Biopharmaceuticals's ticker?

RegeneRx Biopharmaceuticals trades as RGRX on its US listing, under ISIN US75886X3061.

What was RegeneRx Biopharmaceuticals's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.